U.S. Life Sciences Stock News

Innventure, Inc.'s (NASDAQ:INV) value has fallen 14% in the last week, but insiders who sold US$2.3m worth of stock...

Jazz Pharmaceuticals (JAZZ) is back in focus after reporting Phase 3 HERIZON-GEA-01 results for its HER2-targeted drug Ziihera in gastroesophageal cancer, highlighting meaningful gains in progression-free and overall survival versus current treatment. See our latest analysis for Jazz Pharmaceuticals. The Ziihera update lands at a time when Jazz Pharmaceuticals’ share price has been relatively firm, with a 90 day share price return of 22.6% and a 1 year total shareholder return of 40.87%. This...

Wondering if Ducommun at about US$100 a share still offers value, or if most of the easy gains are already on the table? This article is built to help you frame that question clearly. The stock recently closed at US$100.04, with returns of 5.2% over 7 days, 11.1% over 30 days, 3.3% year to date, 54.0% over 1 year, 78.1% over 3 years and 79.1% over 5 years, which indicates that many investors are already paying close attention. Recent coverage around Ducommun has highlighted the company as...

If you are wondering whether Eli Lilly's share price still makes sense at around US$1,108, you are not alone. Many investors are asking what they are really paying for at this level. The stock has recently posted returns of 3.1% over the last 7 days, 11.1% over the last 30 days, 2.6% year to date, 41.8% over the last year and a very large gain over 5 years, which naturally raises questions about growth potential and changes in perceived risk. Recent headlines have focused on Eli Lilly's...

If you are wondering whether American Airlines Group at around US$15.99 is a bargain or a value trap, you are not alone. That is exactly what this article is here to unpack. The stock has returned 4.3% over the last 7 days and 7.6% over the last 30 days, while the 1-year return sits at a 9.1% decline and the 3-year and 5-year returns are 4.2% and 3.0% respectively. Recent headlines have continued to focus on American Airlines Group's debt load, cost pressures and the broader recovery path...

Ripple Effect Asset Management recently disclosed a new position in Antero Midstream (AM), buying 510,000 shares worth about US$9.91 million, after the midstream operator reported stronger third quarter cash generation and lower leverage. See our latest analysis for Antero Midstream. Against this backdrop of stronger cash generation and lower leverage, Antero Midstream’s share price has eased in recent months, with a 30 day share price return showing a 7.98% decline and a 90 day share price...

At CES 2026, LG and Samsung unveiled new audio products aimed squarely at Sonos’s core multi-room and home audio market, intensifying competitive pressure on the company’s ecosystem. This fresh wave of big-brand competition comes just as Sonos is working through missed financial targets and projected near-term revenue softness, sharpening investor focus on its ability to defend share and margins. We’ll now examine how this heightened competition from LG and Samsung could influence Sonos’s...

In recent days, attention on Procter & Gamble has intensified as investors look ahead to its January 22, 2026 earnings webcast under new CEO Shailesh Jejurikar, while analysts reassess the consumer staples sector amid cautious U.S. demand and heightened competitive discounting. At the same time, the company faces a mix of opportunities and challenges, from ongoing product liability litigation and shifting analyst views to its positioning in growing skincare and income-focused ETF markets,...

Key Insights Ispire Technology's significant private companies ownership suggests that the key decisions are influenced...

If you are looking at JPMorgan Chase and wondering whether the current share price reflects its true worth, this article will walk you through how that value stacks up using several common valuation checks. With the stock recently closing at US$326.99 and returns of 1.5% over 7 days, 3.7% over 30 days, 0.5% year to date, 37.2% over 1 year, 151.4% over 3 years and 164.6% over 5 years, many investors are asking if the current level still makes sense. Recent headlines around large US banks have...

If you are wondering whether Warby Parker shares are starting to look compelling at today's price, it helps to step back and look at how the current market value lines up with the underlying business. The stock most recently closed at US$27.07, with returns of 24.2% over the last 7 days, 27.3% over the last 30 days, 19.7% year to date, and 1.7% over the last year, while the 3 year return sits at 54.3%. Recent coverage around Warby Parker has focused on its position as a US eyewear retailer...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Alkermes plc recently reported that the U.S. FDA granted Breakthrough Therapy designation to its investigational oral orexin 2 receptor agonist alixorexton for narcolepsy type 1, following phase 1 and phase 2 data including the large Vibrance-1 study showing statistically significant, dose-dependent improvements in wakefulness versus placebo. This designation, which is reserved for treatments that may offer substantial improvement over existing options for serious conditions, positions...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analyst upgrades and buyback set the stage Ally Financial (ALLY) is in focus after several major banks raised their views on the stock and the company authorized a $2b share repurchase program with no set expiration. These moves, combined with new board appointments and ongoing business tweaks, give investors fresh information to assess how the auto-focused lender’s capital return plans and risk profile line up with their own objectives. See our latest analysis for Ally Financial. Ally...

If you are wondering whether Lam Research shares still offer value after a strong run, or if most of the good news is already reflected in the price, this article unpacks that question in plain terms. Over the last week the stock logged an 18.6% return, with 22.5% over the past month, 9.7% year to date, 166.0% over 1 year and 345.8% over 3 years. These moves naturally raise questions about growth potential and changing risk perceptions. Recent coverage around Lam Research has focused on its...

In recent days, Albemarle drew heightened attention as a series of analyst upgrades and improving lithium market signals highlighted its role as a leading integrated lithium producer serving energy storage, EVs, and other industrial applications worldwide. A distinctive angle from this past week’s developments is growing analyst focus on lithium demand linked to robotics and physical AI, suggesting Albemarle’s end markets may be widening beyond traditional EV and stationary storage...

While Perimeter Solutions, Inc. ( NYSE:PRM ) might not have the largest market cap around , it received a lot of...

If you are wondering whether Qnity Electronics at about US$90.31 is a fair deal or a stretched price, this article walks through what the numbers are actually saying about its value. The stock has recently moved, with returns of 10.6% over the past week, 7.1% over the last 30 days and 6.3% year to date. This naturally raises questions about how much of the valuation story is already reflected in the share price. Recent coverage around Qnity Electronics has focused on its position within the...

Barclays has just initiated coverage on Apple Hospitality REIT (APLE) with an Overweight rating. This move coincides with recent insider buying by the CEO and support from another Overweight call at Cantor Fitzgerald. See our latest analysis for Apple Hospitality REIT. At a share price of US$12.09, Apple Hospitality REIT has a 30 day share price return of 5.5%, while the 1 year total shareholder return shows a 10.2% decline. This suggests recent momentum has picked up after a weaker stretch,...

If you are wondering whether Carrier Global's current share price reflects its underlying value, you are not alone. This article is designed to help you assess that. The stock closed at US$52.57 recently, with returns of a 0.5% decline over 7 days, a 0.9% decline over 30 days, a 1.8% decline year to date and a 22.4% decline over 1 year, set against longer term returns of 20.8% over 3 years and 35.5% over 5 years. Those mixed returns have put more attention on how Carrier Global is being...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Paychex (PAYX) is back in focus after reporting better than expected total revenue growth for the first quarter of fiscal 2025 and rolling out new AI powered tools, including Paychex Flex Engage and Recruiting Copilot. See our latest analysis for Paychex. At a share price of US$111.63, Paychex has seen momentum cool over the past quarter, with a 90 day share price return of 10.85% and a 1 year total shareholder return of 17.91%. This suggests the recent AI product news is arriving after a...

In early January 2026, Johnson & Johnson reported encouraging Phase 2b results for its lupus drug nipocalimab and submitted its OTTAVA robotic surgical system to the FDA for De Novo classification, supported by IDE clinical trial data in multiple upper-abdominal general surgery procedures and a newly approved U.S. trial in inguinal hernia repair. Together, these advances highlight Johnson & Johnson’s push to pair an expanding autoimmune drug pipeline with next-generation surgical robotics,...